UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000036571
Receipt number R000041448
Scientific Title The efficacy of fractional flow reserve-guided percutaneous coronary intervention for patients with angina pectoris: A network meta-analysis
Date of disclosure of the study information 2019/04/24
Last modified on 2019/04/24 11:33:14

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The efficacy of fractional flow reserve-guided percutaneous coronary intervention for patients with angina pectoris: A network meta-analysis

Acronym

The efficacy of fractional flow reserve-guided percutaneous coronary intervention for patients with angina pectoris: A network meta-analysis

Scientific Title

The efficacy of fractional flow reserve-guided percutaneous coronary intervention for patients with angina pectoris: A network meta-analysis

Scientific Title:Acronym

The efficacy of fractional flow reserve-guided percutaneous coronary intervention for patients with angina pectoris: A network meta-analysis

Region

Japan


Condition

Condition

Angina pectoris

Classification by specialty

Cardiology Cardiovascular surgery

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To confirm whether FFR-guided PCI improves prognosis compared to other treatments

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Others

Trial characteristics_2

Others

Developmental phase

Not applicable


Assessment

Primary outcomes

All-cause mortality

Key secondary outcomes

Myocardial infarction


Base

Study type

Others,meta-analysis etc


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

The studies fulfilling the following criteria were included in the analyzes : randomized controlled trials ; studies including patients with AP as study participants; studies involving at least two treatments among FFR-guided PCI, CABG, non-FFR-guided PCI, and MT; and studies with all-cause mortality as an outcome, and studies had at least 1-year follow up period. FFR-guided PCI was defined as PCI for coronary artery stenosis with an FFR of 0.80 or less in the target vessel and non-FFR-guided PCI group was defined as PCI without FFR evaluation.

Key exclusion criteria

Exclusion criteria were as follows: literature reviews or case reports, studies including participants requiring emergency intervention, studies including participants with myocardial infarction within 72 hours prior to enrollment

Target sample size

5000


Research contact person

Name of lead principal investigator

1st name Hiroki
Middle name
Last name Shinohara

Organization

The University of Tokyo Hospital

Division name

Department of Cardiovascular Medicine

Zip code

113-8655

Address

7-3-1 Hongo, Bunkyo-ku, Tokyo, Japan

TEL

03-3815-5411

Email

hshinohara-gun@umin.ac.jp


Public contact

Name of contact person

1st name Hiroki
Middle name
Last name Shinohara

Organization

The University of Tokyo Hospital

Division name

Department of Cardiovascular Medicine

Zip code

113-8655

Address

7-3-1 Hongo, Bunkyo-ku, Tokyo, Japan

TEL

03-3815-5411

Homepage URL


Email

hshinohara-gun@umin.ac.jp


Sponsor or person

Institute

Tokyo University

Institute

Department

Personal name



Funding Source

Organization

Japan Society for the Promotion of Science

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

None

Address

None

Tel

-

Email

-@-


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2019 Year 04 Month 24 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

16187

Results

The study included 16187 patients from 15 RCTs. Network meta analysis (NMA) showed that the all-cause mortality of FFR-guided PCI was not significantly different than those of the other treatment groups (CABG, OR 1.1, 95% CI 0.66, 1.7; non FFR guided PCI, OR 0.85, 95% CI 0.53, 1.4; and MT, OR 0.82, 95% CI 0.52, 1.3). The NMA for MI, including 13548 patients from 12 RCTs, showed that FFR guided PCI tended to reduce the occurrence of MI compared with MT (OR 0.60, 95% CI 0.36, 1.0).

Results date posted

2019 Year 04 Month 03 Day

Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures

All-cause mortality, Myocardial infarction.

Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2019 Year 03 Month 08 Day

Date of IRB

2019 Year 03 Month 08 Day

Anticipated trial start date

2019 Year 03 Month 08 Day

Last follow-up date

2019 Year 03 Month 08 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

Multiple databases were searched for studies from 2000 to 2018, and a NMA was performed to compare outcomes with FFR guided PCI, non FFR guided PCI, CABG, and MT for AP based on estimated odds ratios. Treatments were ranked by the surface under the cumulative ranking curve.


Management information

Registered date

2019 Year 04 Month 22 Day

Last modified on

2019 Year 04 Month 24 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000041448


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name